Medicinova price to sales ratio MNOV

Market value divided by revenue over the last twelve months, since 2013.

Today, Oct 23, 2026: 74.3×
5-year median: 37.2×
Against its 5-year history: 53rd; percentile: 0 is its lowest day, 100 its highest
5-year range: 27.3× to 178×
Peer median: 1.4×

Medicinova's price to sales ratio is 74.3× as of Oct 23, 2026.

That is above its 5-year median of 37.2×, close to the middle of its last 5 years.

Over that time it ranged from 27.3× in Mar 2022 to 178× in Sep 2026.

The median for 9 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

median 37.2×

The dashed line is the 5-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	74.3×	70.1×	178×
2025	n/m a value too high to mean anything
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	28.5×	27.3×	37.2×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	83.5×	52.5×	113×

Against its peers

Companies in Drug Manufacturers - General nearest Medicinova's size, closest first, today.

Company	Price to sales ratio
MNOVMedicinova	74.3×
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
ATNMActinium Pharmaceuticals	n/m
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Medicinova

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.